Korean Circ J.  2010 Jul;40(7):306-307. 10.4070/kcj.2010.40.7.306.

Cardiovascular Safety of Celecoxib on Top of Dual Antiplatelet Therapy

• Hong BK

• KMID: 2225172
• DOI: http://doi.org/10.4070/kcj.2010.40.7.306

Abstract

No abstract available.

MeSH Terms

Pyrazoles
Sulfonamides
Celecoxib
Pyrazoles
Sulfonamides

Reference

1. Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001. 345:433–442.

2. Bombardier C, Laine L, Reicin A, et al. VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000. 343:1520–1528.

3. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: arandomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000. 284:1247–1255.

4. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet. 2004. 364:665–674.

5. Abelson R, Gardiner H. Pfizer warns of risks from its painkiller. The New York Times. 2004. B1.

6. ADAPT Group. Cardiovasucalr and cerebrovascular events in the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). PLoS Clin Trials. 2006. 1:e33.

7. Altman R, Luciardi HL, Muntaner J, et al. Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study. Circulation. 2002. 106:191–195.

8. Chenevard R, Hurlimann D, Bechir M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation. 2003. 107:405–409.

9. Whelton A, White WB, Bello AE, Puma JA, Fort JG. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002. 90:959–963.

10. Lee W, Suh JW, Yang HM, et al. Celecoxib does not attenuate the antiplatelet effects of aspirin and clopidogrel in healthy volunteers. Korean Circ J. 2010. 40:321–327.

11. Wilner KD, Rushing M, Walden C, et al. Celecoxib does not affect the antiplatelet acitivey of aspirin in healthy volunteers. J Clin Pharmacol. 2002. 42:1027–1030.

12. Renda G, Tacconelli S, Capone ML, et al. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther. 2006. 80:264–274.

13. Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med. 2005. 142:157–164.

14. Burklow J, Ralbovsky D. NIH Halts Use of COX-2 Inhibitor in Large Cancer Prevention Trial. 2004. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health.

15. Yang HM, Kim HS, Park KW, et al. Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. Circulation. 2004. 110:301–308.

16. Wang K, Tarakji K, Zhou Z, et al. Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model. J Cardiovasc Pharmacol. 2005. 45:61–67.